ESR1 and breast carcinoma: Since a pivotal role for downstream ER signaling in breast cancer is widely accepted, an anti-hormone therapy (e.g., with anti-estrogens or aromatase inhibitors) to substantially block ER function is frequently employed in the clinical setting.